$RLFTF Vader69 DD (copy) Sometimes, it’s easie
Post# of 653
(Total Views: 611)
Posted On: 02/01/2021 10:55:00 PM
$RLFTF Vader69 DD (copy) Sometimes, it’s easier to see the forest for the trees if you look back at individual events that make up a bigger picture. In the past month or so, we’ve had NO BAD NEWS. Everything is adding up and strongly suggestive results will be good. In recap:
1/27/21 - S4 for BRPA indicates planned BRPA/NRX completion of merger with many great tidbits about OWS stockpiling (100k quarterly with 30k treatments initially), Tesico3 trial, favorable early inhaled data, etc.
1/25/21- Valuation lab report on RLFTF entitled “What a Relief!” with the RLFTF Linked In page post saying: “What a Relief! Read the comprehensive analyst report published by Bob Pooler, ValualtionLab “Prepared to be transformational”. Bob is convinced that 2021 will be a transformational year for RELIEF THERAPEUTICS Holding AG built upon #RLF100 IV potentially reaching positive results in its pivotal U.S. phase 2b/3 trial in #COVID19 induced #ARDS, triggering a potential U.S. Emergency Use Authorization #EUAA) and first commercial sales, including potential stockpiling orders.”
1/25/21 - 4million loan to Acer and proprietary rights to talk with Acer about Negotiate a Collaboration and License Agreement for the Worldwide Development and Commercialization of ACER-001
1/20/21 -Acquisition of Advita for inhaled VIP in trade for 81million shares (25m EUR)…almost as if they knew those shares would be soon worth a lot more
1/19/21 - 50m share subscription from GEM acting as a revolving line of credit in exchange for shares at market price over a set day average
1/12/21 & 1/25/21 -Domain registration of aviptacare.com on 1/12/21 and Swiss trademark registration 1/25/21
12/22/20 - L.J.J. Stijnen announced as Chief Commercial Officer (CCO) effective December 21, 2020. He has an impressive 15year history of commercialization activites at Bristol-Myers Squibb.
12/20/20 - NeuroRx announced inclusion of inhaled Zysami vs remdesivir in the NIH sponsored iSPY trial
1/27/21 - S4 for BRPA indicates planned BRPA/NRX completion of merger with many great tidbits about OWS stockpiling (100k quarterly with 30k treatments initially), Tesico3 trial, favorable early inhaled data, etc.
1/25/21- Valuation lab report on RLFTF entitled “What a Relief!” with the RLFTF Linked In page post saying: “What a Relief! Read the comprehensive analyst report published by Bob Pooler, ValualtionLab “Prepared to be transformational”. Bob is convinced that 2021 will be a transformational year for RELIEF THERAPEUTICS Holding AG built upon #RLF100 IV potentially reaching positive results in its pivotal U.S. phase 2b/3 trial in #COVID19 induced #ARDS, triggering a potential U.S. Emergency Use Authorization #EUAA) and first commercial sales, including potential stockpiling orders.”
1/25/21 - 4million loan to Acer and proprietary rights to talk with Acer about Negotiate a Collaboration and License Agreement for the Worldwide Development and Commercialization of ACER-001
1/20/21 -Acquisition of Advita for inhaled VIP in trade for 81million shares (25m EUR)…almost as if they knew those shares would be soon worth a lot more
1/19/21 - 50m share subscription from GEM acting as a revolving line of credit in exchange for shares at market price over a set day average
1/12/21 & 1/25/21 -Domain registration of aviptacare.com on 1/12/21 and Swiss trademark registration 1/25/21
12/22/20 - L.J.J. Stijnen announced as Chief Commercial Officer (CCO) effective December 21, 2020. He has an impressive 15year history of commercialization activites at Bristol-Myers Squibb.
12/20/20 - NeuroRx announced inclusion of inhaled Zysami vs remdesivir in the NIH sponsored iSPY trial
(1)
(0)Mondobiotech Holding AG Basel (RLFTF) Stock Research Links
$MJ